Is the business good?
How good a business is PODD?
Insulet Corporation earns 22% on the capital it employs against a 9.0% cost of capital, so the business is worth more the bigger it gets.
22%
Return on invested capital · cost of capital 9.0% · 13 points above what the capital costs: growth creates value
- Operating margin
- 17%
Operating margin · Medical Devices median 11% · 12 months to Q2 2026
- Cash conversion
- 0.78×
Cash conversion · 1.72× a year ago · some of the reported profit has not turned into cash yet
- Share count, year on year
- −1.8%
Share count, year on year · bought back, each share owns more of the company
| Year | Operating margin |
|---|---|
| FY2020 | 5.7% |
| FY2021 | 11% |
| FY2022 | 2.9% |
| FY2023 | 13% |
| FY2024 | 15% |
| FY2025 | 18% |
Details›
- Gross margin12 months to Q2 2026
- 71%
- Operating margin12 months to Q2 2026
- 17%
- Net margin12 months to Q2 2026
- 12%
- Free cash flow margin
- 9.6%
- R&D as % of revenue
- 11%
- Revenue, trailing twelve months
- $3.05B
- Free cash flow, trailing twelve months
- $294M
- Net income, trailing twelve months
- $375M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- 22%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion from the cash flow statement.